• Rituxan hits endpoints in late-stage skin disease trial pharmatimes
    June 16, 2019
    Roche has announced that its monoclonal antibody, Rituxan (rituximab), met all primary and secondary endpoints in the Phase III PEMPHIX study.
  • Zerbaxa Meets Primary Endpoints americanpharmaceuticalreview
    September 12, 2018
  • Ionis Announces Phase 3 NEURO-TTR Study of Inotersen Meets Primary Endpoints americanpharmaceuticalreview
    May 16, 2017
PharmaSources Customer Service